About Inhibrx Biosciences, Inc.
https://inhibrx.comInhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.
CEO
Mark Paul Lappe
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 82
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
VIKING GLOBAL INVESTORS LP
Shares:1.79M
Value:$135.74M
PERCEPTIVE ADVISORS LLC
Shares:1.33M
Value:$100.81M
SANOFI
Shares:1.16M
Value:$87.92M
Summary
Showing Top 3 of 111
About Inhibrx Biosciences, Inc.
https://inhibrx.comInhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 ▼ | $33.23M ▲ | $-35.26M ▼ | 0% ▲ | $-2.28 ▼ | $-31.49M ▼ |
| Q2-2025 | $1.3M ▲ | $28.03M ▼ | $-28.65M ▲ | -2.2K% ▼ | $-1.85 ▲ | $-24.85M ▲ |
| Q1-2025 | $0 ▼ | $42.23M ▼ | $-43.31M ▲ | 0% ▲ | $-2.8 ▲ | $-39.95M ▲ |
| Q4-2024 | $100K ▲ | $49.34M ▲ | $-47.87M ▼ | -47.87K% ▼ | $-3.31 ▼ | $-47.18M ▼ |
| Q3-2024 | $0 | $46.04M | $-43.86M | 0% | $-2.84 | $-43.1M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $153.09M ▼ | $177.47M ▼ | $140.64M ▼ | $36.83M ▼ |
| Q2-2025 | $186.57M ▼ | $212.12M ▼ | $143.56M ▼ | $68.56M ▼ |
| Q1-2025 | $216.52M ▲ | $242.64M ▲ | $148.2M ▲ | $94.44M ▼ |
| Q4-2024 | $152.6M ▼ | $180.77M ▼ | $47.18M ▲ | $133.58M ▼ |
| Q3-2024 | $196.33M | $222.56M | $44.09M | $178.47M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-35.26M ▼ | $-33.82M ▼ | $-7K ▼ | $352K ▲ | $-33.48M ▼ | $-33.83M ▼ |
| Q2-2025 | $-28.65M ▲ | $-29.95M ▲ | $0 ▲ | $0 ▼ | $-29.95M ▼ | $-29.95M ▲ |
| Q1-2025 | $-43.31M ▲ | $-35.9M ▲ | $-21K ▼ | $99.84M ▲ | $63.92M ▲ | $-35.92M ▲ |
| Q4-2024 | $-47.87M ▼ | $-43.72M ▼ | $-16K ▲ | $0 | $-43.74M ▼ | $-43.74M ▼ |
| Q3-2024 | $-43.86M | $-30.28M | $-247K | $0 | $-30.53M | $-30.53M |
Revenue by Products
| Product | Q2-2024 | Q4-2024 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 License NonAffiliate | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Mark Paul Lappe
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 82
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
VIKING GLOBAL INVESTORS LP
Shares:1.79M
Value:$135.74M
PERCEPTIVE ADVISORS LLC
Shares:1.33M
Value:$100.81M
SANOFI
Shares:1.16M
Value:$87.92M
Summary
Showing Top 3 of 111